Iovance Biotherapeutics, Inc.

IOVA

US4622601007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:42:42 2024-04-24 pm EDT			5-day change	1st Jan Change
11.92 ^USD	+0.46%		+0.30%	+45.58%

Mar. 29	General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	CI
Mar. 14	Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	MT

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) added to Russell 3000E Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Iovance Biotherapeutics, Inc.

General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	Mar. 29	CI
Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	Mar. 14	MT
Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	Mar. 12
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Mar. 04	MT
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	Mar. 04	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	Mar. 04	DJ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	CI
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	Mar. 01	MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	Feb. 29	MT
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	Feb. 29	MT
Transcript : Iovance Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	Feb. 28	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Iovance Biotherapeutics Insider Bought Shares Worth $45,750,000, According to a Recent SEC Filing	Feb. 21	MT
Iovance Biotherapeutics Insider Bought Shares Worth $292,800, According to a Recent SEC Filing	Feb. 21	MT
Iovance Biotherapeutics Insider Bought Shares Worth $2,287,500, According to a Recent SEC Filing	Feb. 21	MT
Sector Update: Health Care Stocks Lower Late Afternoon	Feb. 20	MT
Sector Update: Health Care	Feb. 20	MT
Top Midday Gainers	Feb. 20	MT
Iovance Biotherapeutics Rises After Analyst Actions, Stock Offering	Feb. 20	MT
Goldman Sachs Raises Price Target on Iovance Biotherapeutics to $19 From $13, Maintains Buy Rating	Feb. 20	MT
Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals	Feb. 20	DJ
Piper Sandler Adjusts Price Target on Iovance Biotherapeutics to $18 From $14, Maintains Overweight Rating	Feb. 20	MT
Iovance Biotherapeutics Prices $211 Million Share Offering; Shares Surge	Feb. 20	MT
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Feb. 20	MT

Chart Iovance Biotherapeutics, Inc.

Duration

Period

More charts

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Iovance Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.86 USD

Average target price

26 USD

Spread / Average Target

+119.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
IOVANCE BIOTHERAPEUTICS, INC.	+45.58%	3.31B
EXACT SCIENCES CORPORATION	-13.38%	11.53B
GUARDANT HEALTH, INC.	-34.09%	2.11B
BGI GENOMICS CO., LTD.	-18.60%	2.05B
VERACYTE, INC.	-27.66%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.63%	1.02B
SEEGENE, INC.	-3.06%	741M
CAREDX, INC	-32.96%	426M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.63%	374M
CURIOX BIOSYSTEMS CO., LTD	+27.44%	372M

Bio Diagnostics & Testing